Arrowhead Pharmaceuticals Inc (ARWR)
24.77
-0.23
(-0.92%)
USD |
NASDAQ |
May 17, 16:00
24.77
0.00 (0.00%)
After-Hours: 20:00
Arrowhead Pharmaceuticals Research and Development Expense (Quarterly): 101.12M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 101.12M |
| December 31, 2023 | 116.49M |
| September 30, 2023 | 99.86M |
| June 30, 2023 | 94.76M |
| March 31, 2023 | 74.88M |
| December 31, 2022 | 83.70M |
| September 30, 2022 | 83.38M |
| June 30, 2022 | 72.18M |
| March 31, 2022 | 75.98M |
| December 31, 2021 | 65.76M |
| September 30, 2021 | 65.77M |
| June 30, 2021 | 59.32M |
| March 31, 2021 | 44.70M |
| December 31, 2020 | 36.56M |
| September 30, 2020 | 43.48M |
| June 30, 2020 | 32.57M |
| March 31, 2020 | 29.44M |
| December 31, 2019 | 23.37M |
| September 30, 2019 | 23.39M |
| June 30, 2019 | 19.29M |
| March 31, 2019 | 20.80M |
| December 31, 2018 | 17.57M |
| September 30, 2018 | 15.99M |
| June 30, 2018 | 12.05M |
| March 31, 2018 | 12.00M |
| Date | Value |
|---|---|
| December 31, 2017 | 12.92M |
| September 30, 2017 | 13.54M |
| June 30, 2017 | 11.14M |
| March 31, 2017 | 11.44M |
| December 31, 2016 | 9.527M |
| September 30, 2016 | 32.34M |
| June 30, 2016 | 9.423M |
| March 31, 2016 | 10.02M |
| December 31, 2015 | 10.34M |
| September 30, 2015 | 10.39M |
| June 30, 2015 | 7.490M |
| March 31, 2015 | 21.78M |
| December 31, 2014 | 17.74M |
| September 30, 2014 | 8.418M |
| June 30, 2014 | 6.392M |
| March 31, 2014 | 5.216M |
| December 31, 2013 | 3.133M |
| September 30, 2013 | 3.247M |
| June 30, 2013 | 1.756M |
| March 31, 2013 | 2.125M |
| December 31, 2012 | 1.577M |
| September 30, 2012 | 2.044M |
| June 30, 2012 | 1.219M |
| March 31, 2012 | 1.359M |
| December 31, 2011 | 0.7691M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
19.29M
Minimum
Jun 2019
116.49M
Maximum
Dec 2023
62.30M
Average
65.77M
Median
Research and Development Expense (Quarterly) Benchmarks
| 89bio Inc | 47.43M |
| Madrigal Pharmaceuticals Inc | 71.24M |
| Viking Therapeutics Inc | 24.10M |
| Akero Therapeutics Inc | 50.65M |
| Sagimet Biosciences Inc | 5.262M |